GACM
BMRN icon

Green Arrow Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Green Arrow Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100,000
Closed -$6.22M – 181
2014
Q2 		$6.22M Buy
+100,000
New +$6.04M 0.78% 38

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Green Arrow Capital Management's BMRN Position: Q4 2014 in Review

Green Arrow Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2014, closing a stake of 130,000 shares — an estimated $9.38M sold.

Green Arrow Capital Management first reported a position in BMRN in Q2 2013 and held it in 5 quarters. The position peaked at $9.38M in Q3 2014. 342 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

  • Green Arrow Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Green Arrow Capital Management sold 130,000 BioMarin Pharmaceuticals shares in Q4 2014, an estimated $9.38M.
  • Green Arrow Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Green Arrow Capital Management's BioMarin Pharmaceuticals position peaked at $9.38M in Q3 2014.
  • 342 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Green Arrow Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.